Product Description: MAO-B-IN-39 (compound11) is a selective monoamine oxidase B (MAO-B) inhibitor. MAO-B-IN-39 inhibits MAO-Bwith an IC50 of 3.61 μM. MAO-B-IN-39 demonstrates a potent NRF2 induction capacity. MAO-B-IN-39 exhibits potent anti-inflammatory and neuroprotective activity in OS (oxidative stress)-related in vitro models. MAO-B-IN-39 demonstrates high liver microsomal stability and favorable pharmacokinetics in mice. MAO-B-IN-39 is potential for Parkinson’s disease (PD) research[1].
Formula: C17H13FN2O
References: [1]Zhang C, et al. Design, Synthesis, and Biological Evaluation of Chiral-Proline Derivatives as Novel HSP90 Inhibitors. ACS Med Chem Lett. 2025 Jan 22;16(2):301-310. /[2]Duarte P, et al. Network-Based Drug Optimization toward the Treatment of Parkinson's Disease: NRF2, MAO-B, Oxidative Stress, and Chronic Neuroinflammation. J Med Chem. 2025 Feb 13;68(3):3495-3517.
Molecular Weight: 280.30
Research Area: Inflammation/Immunology
Target: Keap1-Nrf2;Monoamine Oxidase